Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Net Income towards Common Stockholders: 2015-2024

Historic Net Income towards Common Stockholders for Seres Therapeutics (MCRB) over the last 10 years, with Dec 2024 value amounting to $125.9 million.

  • Seres Therapeutics' Net Income towards Common Stockholders fell 115.63% to -$21.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$41.9 million, marking a year-over-year decrease of 169.53%. This contributed to the annual value of $125.9 million for FY2024, which is 64.79% up from last year.
  • According to the latest figures from FY2024, Seres Therapeutics' Net Income towards Common Stockholders is $125.9 million, which was up 64.79% from $76.4 million recorded in FY2023.
  • In the past 5 years, Seres Therapeutics' Net Income towards Common Stockholders ranged from a high of $125.9 million in FY2024 and a low of -$250.2 million during FY2022.
  • Moreover, its 3-year median value for Net Income towards Common Stockholders was $76.4 million (2023), whereas its average is -$15.9 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first tumbled by 281.46% in 2022, then spiked by 130.54% in 2023.
  • Over the past 5 years, Seres Therapeutics' Net Income towards Common Stockholders (Yearly) stood at -$89.1 million in 2020, then increased by 26.42% to -$65.6 million in 2021, then plummeted by 281.46% to -$250.2 million in 2022, then surged by 130.54% to $76.4 million in 2023, then spiked by 64.79% to $125.9 million in 2024.